MyMyelomaTeam

Are you considering adding teclistamab-cqyv to your current treatment regimen?

Teclistamab-cqyv (Tecvayli) is typically used for relapsed or refractory myeloma after you've already tried at least four other treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody like Dara.

Since Show Full Answer

Are you considering adding teclistamab-cqyv to your current treatment regimen?

Teclistamab-cqyv (Tecvayli) is typically used for relapsed or refractory myeloma after you've already tried at least four other treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody like Dara.

Since you're currently taking Pomalyst (an immunomodulatory drug) with Dara Faspro (an anti-CD38 antibody), teclistamab would generally be considered for later lines of therapy if your current treatment stops working effectively.

Teclistamab works differently than your current medications. It's a bispecific antibody that:
- Binds to BCMA on myeloma cells
- Connects to nearby T cells
- Activates your T cells to destroy the myeloma cells

It's given as a subcutaneous injection (under the skin) rather than an infusion. In clinical trials, teclistamab showed promising results with an overall response rate of about 62%, and at nine months, about 67% of people who responded were still in response.

If you're interested in this treatment option, it's worth discussing with your oncology team whether it might be appropriate for your situation now or as a future option if your current therapy needs adjustment.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

What Is BCMA-Targeted Immunotherapy? (VIDEO)

Bispecific T-Cell Engagers for RRMM: 6 Facts About a New Type of Treatment